FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006570056> ?p ?o ?g. }

• W2006570056 endingPage "968" @default.
• W2006570056 startingPage "958" @default.
• W2006570056 abstract "Background/Aims Hepatocellular carcinoma recurrence after curative treatment adversely influences clinical outcome. It is important to explore adjuvant therapies. This phase II/stage 1 multi-center, randomized trial investigated the safety, optimal dosage and preliminary efficacy of PI-88, a novel heparanase inhibitor, in the setting of post-operative recurrence of HCC according to a Simon’s 2-stage design. Methods Three groups were included: one untreated arm (Group A) and two PI-88 arms (Group B: 160 mg/day; Group C: 250 mg/day). Treatment groups received PI-88 over nine 4-week treatment cycles, followed by a 12-week treatment-free period. Safety and optimal dosage were assessed. Results Overall, 172 patients were randomized and 168 were included in the intention-to-treat (ITT) population. Treatment-related adverse effects included cytopenia, injection site hemorrhage, PT prolongation, etc. Four serious adverse events were possibly related to PI-88 treatment. One (1.8%) group B patients and six (10.5%) group C had hepatotoxicity-related withdrawals. Among the ITT population, 29 patients (50%) in Group A, 35 (63%) in Group B, and 22 (41%) in Group C remained recurrence-free at completion. Calculated T1 value suggested 160 mg/day treatment satisfied the criteria for the next stage of the trial. Conclusions PI-88 at 160 mg/day is optimal and safe, and shows preliminary efficacy as an adjunct therapy for post-operative HCC. Hepatocellular carcinoma recurrence after curative treatment adversely influences clinical outcome. It is important to explore adjuvant therapies. This phase II/stage 1 multi-center, randomized trial investigated the safety, optimal dosage and preliminary efficacy of PI-88, a novel heparanase inhibitor, in the setting of post-operative recurrence of HCC according to a Simon’s 2-stage design. Three groups were included: one untreated arm (Group A) and two PI-88 arms (Group B: 160 mg/day; Group C: 250 mg/day). Treatment groups received PI-88 over nine 4-week treatment cycles, followed by a 12-week treatment-free period. Safety and optimal dosage were assessed. Overall, 172 patients were randomized and 168 were included in the intention-to-treat (ITT) population. Treatment-related adverse effects included cytopenia, injection site hemorrhage, PT prolongation, etc. Four serious adverse events were possibly related to PI-88 treatment. One (1.8%) group B patients and six (10.5%) group C had hepatotoxicity-related withdrawals. Among the ITT population, 29 patients (50%) in Group A, 35 (63%) in Group B, and 22 (41%) in Group C remained recurrence-free at completion. Calculated T1 value suggested 160 mg/day treatment satisfied the criteria for the next stage of the trial. PI-88 at 160 mg/day is optimal and safe, and shows preliminary efficacy as an adjunct therapy for post-operative HCC." @default.
• W2006570056 created "2016-06-24" @default.
• W2006570056 creator A5009124766 @default.
• W2006570056 creator A5017113195 @default.
• W2006570056 creator A5018686864 @default.
• W2006570056 creator A5021689254 @default.
• W2006570056 creator A5037360770 @default.
• W2006570056 creator A5039778548 @default.
• W2006570056 creator A5042881623 @default.
• W2006570056 creator A5047059319 @default.
• W2006570056 creator A5051675160 @default.
• W2006570056 creator A5052086780 @default.
• W2006570056 creator A5058253583 @default.
• W2006570056 creator A5063435962 @default.
• W2006570056 creator A5063466669 @default.
• W2006570056 creator A5064282719 @default.
• W2006570056 creator A5064868087 @default.
• W2006570056 creator A5069232007 @default.
• W2006570056 creator A5072593323 @default.
• W2006570056 creator A5078163693 @default.
• W2006570056 date "2009-05-01" @default.
• W2006570056 modified "2023-10-17" @default.
• W2006570056 title "Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage" @default.
• W2006570056 cites W1963805168 @default.
• W2006570056 cites W1969193065 @default.
• W2006570056 cites W1971837077 @default.
• W2006570056 cites W1973799102 @default.
• W2006570056 cites W1987689694 @default.
• W2006570056 cites W1996523527 @default.
• W2006570056 cites W2021130116 @default.
• W2006570056 cites W2023101728 @default.
• W2006570056 cites W2033285365 @default.
• W2006570056 cites W2034390316 @default.
• W2006570056 cites W2037245133 @default.
• W2006570056 cites W2043382282 @default.
• W2006570056 cites W2048805127 @default.
• W2006570056 cites W2059485540 @default.
• W2006570056 cites W2062162459 @default.
• W2006570056 cites W2064399851 @default.
• W2006570056 cites W2093986504 @default.
• W2006570056 cites W2094873643 @default.
• W2006570056 cites W2099657378 @default.
• W2006570056 cites W2104564014 @default.
• W2006570056 cites W2105187541 @default.
• W2006570056 cites W2109065012 @default.
• W2006570056 cites W2118876881 @default.
• W2006570056 cites W2123528734 @default.
• W2006570056 cites W2136044129 @default.
• W2006570056 cites W2139297732 @default.
• W2006570056 cites W2141155865 @default.
• W2006570056 cites W2153935627 @default.
• W2006570056 cites W2161417398 @default.
• W2006570056 cites W2163486683 @default.
• W2006570056 cites W2165136716 @default.
• W2006570056 cites W2170722580 @default.
• W2006570056 doi "https://doi.org/10.1016/j.jhep.2008.12.023" @default.
• W2006570056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19303160" @default.
• W2006570056 hasPublicationYear "2009" @default.
• W2006570056 type Work @default.
• W2006570056 sameAs 2006570056 @default.
• W2006570056 citedByCount "130" @default.
• W2006570056 countsByYear W20065700562012 @default.
• W2006570056 countsByYear W20065700562013 @default.
• W2006570056 countsByYear W20065700562014 @default.
• W2006570056 countsByYear W20065700562015 @default.
• W2006570056 countsByYear W20065700562016 @default.
• W2006570056 countsByYear W20065700562017 @default.
• W2006570056 countsByYear W20065700562018 @default.
• W2006570056 countsByYear W20065700562019 @default.
• W2006570056 countsByYear W20065700562020 @default.
• W2006570056 countsByYear W20065700562021 @default.
• W2006570056 countsByYear W20065700562022 @default.
• W2006570056 countsByYear W20065700562023 @default.
• W2006570056 crossrefType "journal-article" @default.
• W2006570056 hasAuthorship W2006570056A5009124766 @default.
• W2006570056 hasAuthorship W2006570056A5017113195 @default.
• W2006570056 hasAuthorship W2006570056A5018686864 @default.
• W2006570056 hasAuthorship W2006570056A5021689254 @default.
• W2006570056 hasAuthorship W2006570056A5037360770 @default.
• W2006570056 hasAuthorship W2006570056A5039778548 @default.
• W2006570056 hasAuthorship W2006570056A5042881623 @default.
• W2006570056 hasAuthorship W2006570056A5047059319 @default.
• W2006570056 hasAuthorship W2006570056A5051675160 @default.
• W2006570056 hasAuthorship W2006570056A5052086780 @default.
• W2006570056 hasAuthorship W2006570056A5058253583 @default.
• W2006570056 hasAuthorship W2006570056A5063435962 @default.
• W2006570056 hasAuthorship W2006570056A5063466669 @default.
• W2006570056 hasAuthorship W2006570056A5064282719 @default.
• W2006570056 hasAuthorship W2006570056A5064868087 @default.
• W2006570056 hasAuthorship W2006570056A5069232007 @default.
• W2006570056 hasAuthorship W2006570056A5072593323 @default.
• W2006570056 hasAuthorship W2006570056A5078163693 @default.
• W2006570056 hasConcept C121608353 @default.
• W2006570056 hasConcept C126322002 @default.
• W2006570056 hasConcept C141071460 @default.
• W2006570056 hasConcept C146357865 @default.
• W2006570056 hasConcept C151730666 @default.
• W2006570056 hasConcept C168563851 @default.

• next